Tag Archives: HFPEF

Early Investigator Award The audience was treated to an impressive rapid-fire round with the three finalists for the Early Investigator Award, led by the judging panel; Dr Brian Halliday (Royal Brompton and Harefield Hospitals, London), Dr Rosita Zakeri (King’s College Hospital, London) and Rhys Williams (Cwm Taf Morgannwg University Health Board, Bridgend). Clinical research fellow, Dr Sarah Birkhoelzer (Oxford University) presented her work on the IRON-HEART study, which aimed to determine the impact of iron repletion on cardiac and skeletal muscle energetics in patients with non-ischaemic cardiomyopathy with reduced ejection fraction. S

Preparing for the next 25 years Opening the meeting, BSH Chair Professor Roy Gardner (University of Glasgow) spoke about the BSH‘s aim to reduce HF mortality by 25% in 25 years, which would need the bringing together of all stakeholders to improve: Prevention strategies Identifying those at risk Early accurate diagnosis Appropriate treatment In his speech, he encouraged us to be more ambitious for further progress, to raise awareness of HF, and to educate more widely to achieve further progress and benefit more patients. 25 Fellows for 25 years Table 1. The new British Society for Heart Failure Fellows John Baxter, Sunderland Lynd

ESC President, Professor Barbara Casadei Heart failure highlights PARAGON-HF fails primary end point but benefits for some Heart failure was a key theme of this year’s congress, accounting for more than 1,000 presentations. In the first hotline session of the Congress, the keenly awaited results from PARAGON-HF (Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction) were presented.1 Up to 64 million people worldwide have heart failure, and that number is rising as the population ages. Evidence-based treatment has focused on about half of these patients who have heart failure with reduced ejection fraction (<

Landmark trials in heart failure – 30 years from CONSENSUS With 2017 marking the 30th year since the publication of CONSENSUS,1 which first reported a reduction in mortality with enalapril versus placebo in patients with advanced heart failure (HF), the BCS held a dedicated session to review the seminal clinical trials and advances in chronic heart failure management in this period. Dr Rosita Zakeri (Royal Brompton Hospital, London) reviewed this session for us and spoke to the BJC afterwards. Rosita Zakeri The era of vasodilator therapy for heart failure began in the 1990s. Professor Karl Swedberg (University of Gothenberg, Sweden) began

Anaemia was one of several problems chosen for a case-based discussion in a session on common non-cardiac co-morbidities. Dr Callum Chapman (West Middlesex University Hospital) presented the case of an elderly patient with known coeliac disease who had undergone transcatheter aortic valve implantation, which resulted in a paraprosthetic leak and impingement of the mitral valve. Unfortunately despite medical management of the leak she presented to the elderly care service in New York Heart Association (NYHA) Class III heart failure and was extremely oedematous. Blood tests revealed an iron deficiency anaemia and a reduced transferrin saturati